We propose that the differences in the level of NLRP3 activation in tumor cell lines are related to variations in the inflammatory nature of the individual tumor types, where pro-inflammatory cytokines produced by the tumor could act as priming agents, instead of LPS (72, 98–100). This evidence concerns the gene NLRP3 and neoplasm.